According to Zacks, “Emergent aims to offer specialized products to health care providers and governments to fulfil unmet medical needs and combat threats posed by serious diseases to human health. The company derives the majority of revenues from sales of its key product BioThrax to its principal purchaser, the U.S. government. Its sole dependence on BioThrax for revenues has its inherent risks and thus remains a concern. Any hiccup in the production of BioThrax could hurt the company’s top line significantly. Moreover, Emergent faces competition from a number of companies with biodefense products or candidates under development for both the U.S. government procurement and development resources. Stiff competition remains a concern as well. However, Emergent has secured a multi-year contract with the BARDA, for the advanced development and delivery of its next generation anthrax vaccine candidate, NuThrax. Its approval will be a huge boost for the company.”
A number of other research analysts also recently commented on the stock. Singular Research dropped their price objective on shares of Emergent Biosolutions from $44.00 to $40.00 and set a buy rating for the company in a research note on Tuesday, June 28th. Cowen and Company downgraded shares of Emergent Biosolutions from an outperform rating to a market perform rating in a research note on Wednesday, June 22nd. Wells Fargo & Co. set a $41.00 price objective on shares of Emergent Biosolutions and gave the company a buy rating in a research note on Saturday, October 1st. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Emergent Biosolutions from $45.00 to $36.00 and set an overweight rating for the company in a research note on Friday, August 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $40.17.
Emergent Biosolutions (NYSE:EBS) opened at 32.23 on Wednesday. The company has a 50-day moving average of $28.05 and a 200-day moving average of $34.09. The stock has a market cap of $1.30 billion, a P/E ratio of 23.05 and a beta of 1.12. Emergent Biosolutions has a 52 week low of $26.12 and a 52 week high of $44.38.
Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. Emergent Biosolutions had a net margin of 11.61% and a return on equity of 11.93%. The firm earned $101.49 million during the quarter, compared to analyst estimates of $111.20 million. During the same period in the previous year, the firm posted $0.36 EPS. The company’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, analysts predict that Emergent Biosolutions will post $1.03 EPS for the current fiscal year.
Hedge funds have recently bought and sold shares of the company. PineBridge Investments L.P. increased its stake in Emergent Biosolutions by 5.4% in the second quarter. PineBridge Investments L.P. now owns 3,964 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 202 shares during the period. Legal & General Group Plc increased its stake in Emergent Biosolutions by 6.3% in the first quarter. Legal & General Group Plc now owns 4,498 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 265 shares during the period. Teacher Retirement System of Texas increased its stake in Emergent Biosolutions by 22.5% in the second quarter. Teacher Retirement System of Texas now owns 4,707 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 866 shares during the period. Howe & Rusling Inc. increased its stake in Emergent Biosolutions by 3.0% in the second quarter. Howe & Rusling Inc. now owns 4,875 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 140 shares during the period. Finally, Springbok Capital Management LLC bought a new position in Emergent Biosolutions during the first quarter worth $192,000. 89.95% of the stock is owned by hedge funds and other institutional investors.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.